0001090872false00010908722024-01-052024-01-05





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 5, 2024
 
AGILENT TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware001-1540577-0518772
(State or other jurisdiction(Commission(IRS Employer
of incorporation)File Number)Identification No.)
 
5301 Stevens Creek Boulevard, Santa Clara, CA 95051
(Address of Principal Executive Offices) (Zip Code)
 
Registrant’s telephone number, including area code (800) 227-9770
 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
TITLE OF EACH CLASSTRADING SYMBOL(S)NAME OF EACH EXCHANGE ON WHICH REGISTERED
COMMON STOCK, $0.01 PAR VALUEANew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 




Item 7.01     Regulation FD Disclosure.
 
On December 20, 2023, we issued a press release announcing that we had moved our Cell Analysis Division into the Diagnostics and Genomics Group (DGG) business segment from the Life Sciences and Applied Markets Group (LSAG) business segment to further strengthen growth opportunities for both organizations. Following this reorganization, we will continue to have three business segments (LSAG, DGG and Agilent CrossLab), each of which will continue to comprise a reportable segment.

We are furnishing this Current Report on Form 8-K to present selected segment information that reflect changes in our reportable segments related to the changes in our organizational structure. Beginning with the quarter ending January 31, 2024, our financial statements will reflect the new reporting structure with prior periods recast accordingly.

The information contained in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 18. Furthermore, the information contained in this report shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

Item 9.01.              Financial Statements and Exhibits.
 
(d) Exhibits
 
The following is furnished as an exhibit to this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended:
 
Exhibit No. Description
 Selected segment information for the fiscal quarters ended January 31, 2021, 2022 and 2023, April 30, 2021, 2022 and 2023, July 31, 2021, 2022 and 2023 and October 31, 2021, 2022 and 2023 and fiscal years ended October 31, 2021, 2022 and 2023.
104 Cover page interactive data file (embedded within the Inline XBRL document)


2



SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 AGILENT TECHNOLOGIES, INC.
  
  
 By:/s/ P. Diana Chiu
 Name:P. Diana Chiu
 Title:Vice President, Interim General Counsel
and Secretary
  
  
  
Date: January 5, 2024 






3


AGILENT TECHNOLOGIES, INC.
LIFE SCIENCES AND APPLIED MARKETS SEGMENT
(Unaudited)
All periods below were recast to reflect the movement of the Cell Analysis division to our Diagnostics and Genomics business segment from our Life Sciences and Applied Markets business segment.
(In millions, except margins data)FY23
Q1Q2Q3Q4Total
Revenue$943 $874 $854 $839 $3,510 
Gross margin %61.5 %59.8 %60.1 %59.5 %60.3 %
Research and development expenses$67 $69 $62 $64 $262 
Selling, general and administrative expenses$213 $210 $186 $196 $805 
Income from operations$300 $244 $265 $240 $1,049 
Operating margin %31.8 %27.9 %31.0 %28.6 %29.9 %
FY22
Q1Q2Q3Q4Total
Revenue$900 $799 $921 $1,010 $3,630 
Gross margin %60.5 %58.9 %60.4 %60.6 %60.1 %
Research and development expenses$66 $63 $64 $64 $257 
Selling, general and administrative expenses$207 $204 $207 $211 $829 
Income from operations$271 $204 $285 $337 $1,097 
Operating margin %30.1 %25.5 %31.0 %33.3 %30.2 %
FY21
Q1Q2Q3Q4Total
Revenue$835 $797 $811 $861 $3,304 
Gross margin %60.0 %59.5 %60.1 %59.3 %59.7 %
Research and development expenses$59 $62 $60 $63 $244 
Selling, general and administrative expenses$202 $209 $203 $206 $820 
Income from operations$240 $203 $224 $242 $909 
Operating margin %28.7 %25.5 %27.7 %28.1 %27.5 %

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, business exit and divestiture costs, special compliance costs and change in fair value of contingent consideration.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.





1

AGILENT TECHNOLOGIES, INC.
DIAGNOSTICS AND GENOMICS SEGMENT
(Unaudited)
All periods below were recast to reflect the movement of the Cell Analysis division to our Diagnostics and Genomics business segment from our Life Sciences and Applied Markets business segment.
(In millions, except margins data)FY23
Q1Q2Q3Q4Total
Revenue$432 $456 $422 $445 $1,755 
Gross margin %52.6 %53.7 %53.5 %53.7 %53.4 %
Research and development expenses$47 $48 $38 $44 $177 
Selling, general and administrative expenses$107 $104 $92 $94 $397 
Income from operations$73 $93 $96 $101 $363 
Operating margin %16.9 %20.5 %22.7 %22.7 %20.7 %
FY22
Q1Q2Q3Q4Total
Revenue$415 $455 $438 $458 $1,766 
Gross margin %54.2 %56.7 %55.8 %53.1 %55.0 %
Research and development expenses$42 $44 $43 $45 $174 
Selling, general and administrative expenses$104 $99 $103 $101 $407 
Income from operations$79 $115 $99 $97 $390 
Operating margin %19.0 %25.4 %22.6 %21.2 %22.1 %
FY21
Q1Q2Q3Q4Total
Revenue$382 $399 $432 $442 $1,655 
Gross margin %54.4 %55.7 %55.5 %55.4 %55.3 %
Research and development expenses$35 $37 $40 $44 $156 
Selling, general and administrative expenses$93 $93 $96 $96 $378 
Income from operations$80 $92 $104 $105 $381 
Operating margin %20.8 %23.1 %24.1 %23.8 %23.0 %

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, business exit and divestiture costs, special compliance costs and change in fair value of contingent consideration.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.






2

AGILENT TECHNOLOGIES, INC.
AGILENT CROSSLAB SEGMENT
(Unaudited)
No change. Included to show our business segments structure in its entirety.
(In millions, except margins data)FY23
Q1Q2Q3Q4Total
Revenue$381 $387 $396 $404 $1,568 
Gross margin %48.5 %47.0 %50.9 %50.4 %49.3 %
Research and development expenses$9 $8 $8 $8 $33 
Selling, general and administrative expenses$73 $71 $65 $67 $276 
Income from operations$103 $103 $129 $128 $463 
Operating margin %27.0 %26.6 %32.7 %31.7 %29.5 %
FY22
Q1Q2Q3Q4Total
Revenue$359 $353 $359 $381 $1,452 
Gross margin %47.5 %47.1 %47.0 %48.6 %47.6 %
Research and development expenses$8 $7 $8 $9 $32 
Selling, general and administrative expenses$72 $72 $72 $72 $288 
Income from operations$91 $87 $88 $104 $370 
Operating margin %25.2 %24.6 %24.6 %27.4 %25.5 %
FY21
Q1Q2Q3Q4Total
Revenue$331 $329 $343 $357 $1,360 
Gross margin %46.8 %45.3 %46.6 %48.3 %46.8 %
Research and development expenses$9 $8 $9 $8 $34 
Selling, general and administrative expenses$70 $72 $67 $70 $279 
Income from operations$76 $69 $84 $94 $323 
Operating margin %23.1 %21.0 %24.4 %26.3 %23.8 %

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, business exit and divestiture costs, special compliance costs and change in fair value of contingent consideration.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.
3
v3.23.4
Document and Entity Information Document
Jan. 05, 2024
Document and Entity Information [Abstract]  
Entity Central Index Key 0001090872
Title of 12(b) Security COMMON STOCK, $0.01 PAR VALUE
Entity Incorporation, State or Country Code DE
Document Type 8-K
Document Period End Date Jan. 05, 2024
Entity Registrant Name AGILENT TECHNOLOGIES, INC.
Entity Tax Identification Number 001-15405
Entity Tax Identification Number 77-0518772
Entity Address, Address Line One 5301 Stevens Creek Boulevard
Entity Address, City or Town Santa Clara
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95051
City Area Code (800)
Local Phone Number 227-9770
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Trading Symbol A
Security Exchange Name NYSE
Amendment Flag false
Agilent Technologies (NYSE:A)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more Agilent Technologies Charts.
Agilent Technologies (NYSE:A)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more Agilent Technologies Charts.